Project Details
Description
A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
| Status | Finished |
|---|---|
| Effective start/end date | 8/1/15 → 6/30/21 |
Funding
- ASTELLAS PHARMA, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.